The Schain Research team

Malin Almgren, PhD

CEO

Dr Almgren holds a MSc in Chemistry from Stockholm University and a PhD in Medicine from Karolinska Institutet. With over 20 years in medical research, she has deep knowledge in several fields including genetics, immunology, neuroscience, and oncology including clinical trials and collaborations with industry. As an Assistant Professor at Karolinska Intitutet, she focused on environmental impact on autoimmunity and neonatology.
In addition to her scientific experience, she has a second career in finance, having held positions as Director for strategic partnerships at a Swedish asset manager with focus on sustainable investment, and most recently as financial advisor, supporting M&A transactions in the healthcare sector at Experia Corporate Finance Advisors AB.

Christina Jones, PhD

Scientific Director and Data Protection Officer

Dr Jones has a PhD in Developmental Biology from Monash University, Australia, and has worked as a postdoctoral researcher at Karolinska Institutet, studying human kidney regeneration. Christina has experience in preclinical research, project management, commercialization, academia/industry/clinical partnerships and scientific writing.

Frida Schain, PhD

Senior Scientific Advisor

Dr Schain has a MSc in Molecular Biology from Lund University and a PhD in Medicine, Hematology, from Karolinska Institutet, where she focused on molecular aspects of inflammation and lymphoma pathogenesis. Her broad experience ranges from academic research and early drug discovery to the medical device and pharmaceutical industry. Her pharmaceutical industry experience includes leadership roles in medical affairs, real-world evidence, epidemiology and commercial aspects of drug development.

Kelvin Kwok, PhD

Senior Scientist

Dr Kwok studied Biochemistry at Oxford University and did his PhD in Endocrinology at University of Hong Kong. He has also worked as a postdoctoral researcher at Karolinska Institutet focusing on metabolic diseases before joining Schain Research. He is experienced in pre-clinical and clinical research, data analytics and scientific writing.

Tina Jacob, PhD

Senior Scientist

Dr Jacob holds a PhD from Karolinska Institutet. Before joining Schain Research she focused on dermatology, oncology, and diagnostic assays. She is experienced in pre-clinical research, data analytics, ethical applications, project management, and scientific writing.

Moyukh Chowdhury, MD, MPH

Scientist

Dr Chowdhury has completed his MD from Southern Medical University, China, and Masters in Public Health from Umeå University as a Swedish institute scholar. He has a diverse research experience from global public health to Nordic real-world evidence and market access. He has been involved in evaluating several international public health interventions and multi-country epidemiological studies besides the clinical work.

Ahmad Abbadi, MD

Scientist

Dr Abbadi holds an MD from Jordan University of Science and Technology and a MSc in Medical Sciences in Public Health Epidemiology from Karolinska Institutet. He has previously worked with academia, governmental and non-governmental organizations. He has experience in tobacco control, urological epidemiology, project management, clinical research, data analysis and scientific writing.

Victoria Wyckelsma, PhD

Senior Scientist

Dr Wyckelsma has a PhD in Physiology from Victoria University, Australia. Before joining Schain Research, she completed postdoctoral fellowships in Australia and at Karolinska Institutet focusing on exercise and muscle physiology. Victoria is experienced in preclinical and clinical research, project management, scientific writing, ethics applications and data analytics.

Rafiq Muhammad, MD, MIHMEP, PhD

Scientist

Dr Muhammad completed his MD from Khyber Medical University, Pakistan, Masters in Healthcare Management (MIHMEP) from SDA Bocconi School of Management, Italy, and a PhD in Healthcare Data Sciences from Karolinska Institutet, where he worked on predictive modeling for patients with multiple chronic conditions. He is experienced in healthcare predictive analytics, public health interventions and disease surveillance, systematic literature reviews and scientific writing.

Eva Herweijer, PhD

Senior Scientist

Dr Herweijer has a PhD in Epidemiology from Karolinska Institutet, where she worked on a register based evaluation of HPV vaccination programs. Eva has over 10 years of experience within real-world evidence, including several years of working in industry as a senior research consultant and analyst. Eva is experienced in study design, data analytics, scientific writing and project management. 

Erwei Zeng, PhD

Scientist

Dr Zeng has a PhD in Epidemiology from Karolinska Institutet. Prior to joining Schain Research, Dr Zeng completed her masters and PhD focusing on population-based oncology research. Her expertise spans over critical components of treatment analysis in RWE including comparative effectiveness, determinants of treatment, and safety. She is also highly experienced in using utilizing data from national health registers to understand disease burden and survival outcomes.

Maria Wahlström

Manager Finance and HR

Maria holds a degree in accounting economics and payroll management with long and broad experience with project, sales, and marketing management within several industries and brands. She is also responsible for our Human Resources department and payroll management.

Board of Directors

Lars Johansson

Chairman of the Board

Lars Johansson brings 30 years of experience from the medtech and pharmaceutical industry, including 13 years as General Manager for Janssen, Johnson & Johnson in the Nordics. Lars has a track record of being an extraordinary leader and his experience covers all strategic and operational aspects of bringing innovative treatments to patients.

Frida Schain, PhD

Founder and Board Member

Dr Schain has a MSc in Molecular Biology from Lund University and a PhD in Medicine, Hematology, from Karolinska Institutet, where she focused on molecular aspects of inflammation and lymphoma pathogenesis. Her broad experience ranges from academic research and early drug discovery to the medical device and pharmaceutical industry. Her pharmaceutical industry experience includes leadership roles in medical affairs, real-world evidence, epidemiology and commercial aspects of drug development. Most recently, she was a Global Director at Janssen, Johnson & Johnson, focusing on evidence generation from a market access and medical affairs perspective. In this role she was also a member of the global real-world evidence leadership team.

Malin Heyman

Board Member

Malin Heyman has more than 20 years of experience from financial services at SEB and Nasdaq as well as co-founder of a fintech company, Swimbird AB. Her roles have ranged from business development, sales to leadership as head of financial services and products. With extensive experience from strategic work, process development and digitalisation, Malin will bring significant value to the organisation as we continue to develop our capabilities and services in evidence generation and health data sciences.

Magnus Björkholm, MD, PhD

Senior Professor of Medicine, Karolinska University Hospital and Karolinska Institutet

Professor Björkholm´s research is focused on clinical, experimental and epidemiological studies of malignant hematological diseases, with particular expertise in lymphoma, leukemia, myeloma and myeloproliferative neoplasms. He has authored more than 500 peer reviewed papers.